ASSOCIATION BETWEEN POLYMORPHISM OF THE CYP2D6 GENE AND EFFICACY AND SAFETY PROFILE OF HALOPERIDOL IN PATIENTS WITH ALCOHOL ADDICTION
Issue:
3
Year:
2016
The study involved 20 men with alcohol addiction. The efficacy and safety of haloperidol was evaluated by international psychometric scales. The genotype of CYP2D6 was investigated by real-time PCR. The study revealed a statistically significant patterns between the polymorphism of CYP2D6 and the efficacy and safety of haloperidol.
Keywords:
psychiatry–narcology
haloperidol
polymorphism
CYP2D6
side effects
alcoholism
References:
- Sivolap Ju.P. Ratsional'nye podhody k primeneniju nejroleptikov v narkologicheskoj praktike // Zdorovaja Ukraina. – 2008; 7 (1): 83–4.
- Butwicka A1., Krystyna S., Retka W. et al. Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency // Eur. J. Pediatr. – 2014; 173 (12): 1639–42.
- Gasso P., Papagianni K., Bobadilla R. et al. Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers // Pharmacogenomics. – 2013; 14 (13): 1551–63.
- Van der Weide K1., van der Weide J. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, pimozide, and risperidone in psychiatric patients // J. Clin. Psychopharmacol. – 2015; 35 (3): 228–36.
- Nakamura A1., Mihara K., Nemoto K. et al. Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia // Ther. Drug. Monit. – 2014; 36 (6): 815–8.
- Jiang X., Shen H., Yu A. Pinolinemay be used as a probe for CYP2D6 activity // Drug Metab. Dispos. – 2009; 37 (3): 443–6.
- Langaee T., Hamadeh I., Chapman A. et al. A Novel Simple Method for Determining CYP2D6 Gene Copy Number and Identifying Allele(s) with Duplication/ Multiplication // PLoS One. – 2015; 10 (1): e0113808.
- Crews K., Gaedigk A., Dunnenberger H. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype // Clin. Pharmacol. Ther. – 2012; 91 (2): 321–6.
- Kukes V.G., Grachev S.V., Sychev D.A. i dr. Metabolizm lekarstvennyh sredstv: nauchnye osnovy personalizirovannoj meditsiny / M.: GEOTAR- Media, 2008.
- Zanger U., Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry // Naunyn Schmiedebergs Arch. Pharmacol. – 2004; 369 (1): 23–37.